royal dsm nv reported on tuesday a rise in adjusted ebitda from continuing operations for the second quarter of 2022 beating market views and said that it continues to expect further growth for the year as a whole the dutch nutrition health and bioscience company reported an adjusted earnings before interest taxes depreciation and amortization from continued operationsthe companys preferred metric which strips out exceptional and other oneoff itemsof 379 million euros 3889 million up from eur360 million a year earlier adjusted ebitda was expected to come in at eur360 million taken from the companys compiled consensus sales from continuing operations for the quarter increased to eur211 billion compared with eur179 billion for the year earlierperiod when they were anticipated to be eur179 billion according to royal dsms compiled forecasts for the period sales of the health nutrition and bioscience division rose 19 to eur950 million it added regarding its outlook the company said that the strong volume and price momentum it experienced in june will continue into the third quarter and that it continues to expect to deliver a highsingle digit adjusted ebitda increase for 2022